2022•Thoracic CancerOpen access
ERBB2 exon 20 insertions are rare in Brazilian non‐small cell lung cancer
Rodrigo de Oliveira Cavagna, Beatriz Garbe Zaniolo, Flávia Escremim de Paula, Gustavo Nóriz Berardinelli, Iara Viana Vidigal Santana, Eduardo Caetano Albino da Silva, Josiane Mourão Dias, Alexandre Arthur Jacinto, Rachid Eduardo Noleto da Nóbrega Oliveira, Pedro De Marchi, Letícia Ferro Leal, Rui Manuel Reis
Open full text 6 citations
Abstract
ERBB2 exon 20 insertions may impact the clinical management of lung cancer patients. However, the frequency of ERBB2 exon 20 insertions in lung cancer patients in Brazil is scarce. Here, we analyzed 722 Brazilian non-small cell lung cancer (NSCLC) patients from Barretos Cancer Hospital that were indicated to require routine lung cancer molecular testing. ERBB2 exon 20 insertions were evaluated by a targeted panel using next-generation sequencing (NGS). Clinicopathological and molecular data were collected from patient medical records. Among the 722 NSCLC patients, 85.2% had lung adenocarcinomas, 53.9% were male, 66.8% were quitter or current smokers, and 63.2% were diagnosed at an advanced stage of the disease. We identified 0.8% (6/722) of patients who harbored the insertion p.(Tyr772_Ala775dup) at exon 20 of the ERBB2 gene. All ERBB2 mutated patients were diagnosed with lung adenocarcinoma, were never smokers, and wild-type for EGFR, KRAS, and ALK hotspot alterations. Less than 1% of Brazilian NSCLC patients harbor ERBB2 exon 20 insertions, yet they could benefit in future from the new drugs in development.
Open-access reader